The GLP-1 Gold Rush: How Telehealth Turned Weight-Loss Drugs Into a Regulatory Battlefield
The demand for weight-loss drugs has exploded in recent years, turning medications like semaglutide and tirzepatide into some of the most sought-after prescriptions in modern medicine. What began as a clinical breakthrough for diabetes has rapidly evolved into something much larger. These drugs are now at the center of a cultural, medical, and commercial phenomenon […]
Semaglutide for MASH and Liver Disease: How Diabetes Drugs Move into Hepatology
Introduction The landscape of liver disease treatment is undergoing a major transformation, and for the first time, diabetes medications, and not traditional hepatology drugs, are at the center of it. As metabolic dysfunction emerges as the dominant driver of fatty liver disease, researchers and clinicians are turning to GLP-1 medications such as semaglutide to address […]
Microdosing Semaglutide: Trend or Trap? What the Evidence Says in 2025
By 2025, one of the most surprising trends in the weight-loss world isn’t a new drug it’s a new way people are using an old one. Across TikTok, Reddit, and telehealth forums, users are experimenting with microdosing semaglutide: taking doses far below FDA-approved starting amounts in hopes of avoiding nausea while still losing weight. Some […]
Ozempic Face, Ozempic Rebound, and Long-Term Use
Introduction Few medications have reshaped public conversation around weight, health, and aging as dramatically as semaglutide. By 2025, search terms like “Ozempic face” and “Ozempic rebound weight gain” have become cultural fixtures, shorthand for anxieties about how rapid weight loss looks, what long-term treatment requires, and what happens when the medication stops. While these phrases […]
SOUL: Oral Semaglutide (Rybelsus) Demonstrates First-Ever Reduction in MACE for High-Risk Type 2 Diabetes Patients
Why the SOUL Trial Represents a Breakthrough for Oral GLP-1 Therapy The SOUL trial positions oral semaglutide in an entirely new therapeutic category. Until now, every GLP-1 receptor agonist with proven cardiovascular protection had been administered by injection. Liraglutide, injectable semaglutide, dulaglutide – each demonstrated reductions in major adverse cardiovascular events, establishing GLP-1 RAs as […]